Johnson & Johnson (NYSE:JNJ), a well-known healthcare company with a diverse range of products in pharmaceuticals, medical devices, and consumer health, competes with giants like Pfizer and Merck. Recently, Terrance Flynn from Morgan Stanley set a price target of $262 for JNJ, suggesting a potential upside of 16.73% from its current trading price of $224.44.
Johnson & Johnson has announced an optimistic financial outlook for 2026, projecting sales between $100 billion and $101 billion. This forecast exceeds the Zacks Consensus Estimate of $98.5 billion, indicating strong growth potential. The company also expects adjusted earnings per share to range from $11.43 to $11.63, reflecting confidence in its financial performance.
The company's Innovative Medicine segment is expected to grow despite the loss of exclusivity for Stelara. This growth is driven by products like Darzalex and Tremfya, along with new product launches. The MedTech segment is also projected to experience stronger growth, although it may face challenges from China's volume-based procurement policies.
Currently, JNJ is trading at $224.44, with a recent price increase of $2.95, marking a 1.33% rise. The stock has fluctuated between a low of $220.70 and a high of $225.50 today, with the latter being its highest price over the past year. The company's market capitalization is approximately $540.7 billion, with a trading volume of 6,976,710 shares.
Over the past year, JNJ's stock price has ranged from a low of $141.50 to its current high. This volatility reflects the dynamic nature of the healthcare industry and the company's ability to adapt to market changes. As JNJ continues to innovate and expand its product offerings, it remains a key player in the global healthcare market.
